Stockscreener 앱 받기
3.23
1.57%
0.05
시간 외 거래:
3.19
-0.04
-1.24%
Dare Bioscience Inc 주식(DARE)의 최신 뉴스
Dare Bioscience (DARE) Upgraded to Buy: Here's What You Should Know - MSN
Dare Bioscience files to sell 2.75M shares of common stocks by selling shareholders - MSN
Daré Bioscience, Inc. (NASDAQ:DARE) Q3 2024 Earnings Call Transcript - Insider Monkey
Dare Bioscience Inc (DARE) Q3 2024 Earnings Call Highlights: Str - GuruFocus.com
Dare Bioscience Inc (DARE) Q3 2024 Earnings Call Highlights: Strategic Advancements and ... - Yahoo Finance
Dare Bioscience Inc (DARE) Quarterly 10-Q Report - Quartzy
Dare Bioscience, Inc. (DARE) Reports Q3 Loss, Lags Revenue Estimates - Yahoo Finance
Form 10-Q Dare Bioscience, Inc. For: Sep 30 - StreetInsider.com
Daré Bioscience Reports Third Quarter 2024 Financial Results and Provides Company Update - GlobeNewswire
Daré Bioscience Secures $35.7M in Funding, Cuts R&D Costs by 60% in Q3 Report | DARE Stock News - StockTitan
Daré Bioscience Announces Grant to Support Development of a - GlobeNewswire
Daré Bioscience secures $10.7 million grant from Gates Foundation - Investing.com India
Daré Bioscience secures $10.7 million grant from Gates Foundation By Investing.com - Investing.com UK
Daré Bioscience Lands $10.7M Gates Foundation Grant for Novel Contraceptive Development | DARE Stock News - StockTitan
Daré Bioscience (DARE) Scheduled to Post Earnings on Thursday - Defense World
Daré Bioscience to Host Third Quarter 2024 Financial Results and Company Update Conference Call and Webcast on November 14, 2024 - The Manila Times
Daré Bioscience to Host Third Quarter 2024 Financial - GlobeNewswire
Daré Bioscience to Report Q3 2024 Earnings, Host Conference Call November 14 | DARE Stock News - StockTitan
Daré Lands $25M for Women-Centric Pipeline - San Diego Business Journal
Dare BioscienceCatering To Women - RTTNews
Is Bavarian Nordic (BVNRY) Stock Outpacing Its Medical Peers This Year? - Yahoo Finance
Will It Be A December To Remember For Daré Bioscience? - RTTNews
Daré Bioscience (NASDAQ:DARE) Publishes Corporate Presentation - Defense World
Daré Bioscience Enhances Investor Engagement with New Presentation - TipRanks
Daré Bioscience enters into $15M stock purchase agreement - MSN
Dare Bioscience shares retain Buy rating on funding reward By Investing.com - Investing.com Canada
Dare Bioscience awarded $10M for HPV treatment development - Investing.com India
Dare Bioscience awarded $10M for HPV treatment development By Investing.com - Investing.com South Africa
Daré Bioscience Selected to Receive $10 Million Award from ARPA-H’s Sprint for Women’s Health - The Bakersfield Californian
Daré Bioscience Enters Purchase Agreement with Lincoln Park Capital Fund - Defense World
Dare Bioscience secures $15 million funding agreement By Investing.com - Investing.com Australia
Dare Bioscience secures $15 million funding agreement - Investing.com
Daré Bioscience Announces Common Stock Purchase Agreement - GlobeNewswire
Daré Bioscience Announces Common Stock Purchase Agreement for up to $15 Million with Lincoln Park Capital Fund, LLC - StockTitan
Brookline Capital Downgrades Daré Bioscience (DARE) - MSN
Bill Gates helped fund birth control microchip but didn't invent it | Fact check - USA TODAY
Dye & Durham Limited - Baystreet.ca
DADA’s 2023 Market Dance: Down -64.46% – Time to Invest? - The InvestChronicle
Barrow Hanley Mewhinney & Strauss LLC Raises Stake in Darling Ingredients Inc. (NYSE:DAR) - Defense World
Darling Ingredients Inc. (NYSE:DAR) Shares Sold by Meiji Yasuda Asset Management Co Ltd. - Defense World
MDA Space shares target raised on Telesat Lightspeed deals By Investing.com - Investing.com Australia
The Dare Announce 2024 Australian Headlining Shows - Music Feeds
The Dare Shares Inaugural Australian Tour Dates - The Music
ADMA Biologics stock soars to all-time high of $19.36 - Investing.com
The massive, untapped opportunity in women’s health - BioWorld Online
Daré Bioscience (NASDAQ:DARE) Share Price Crosses Below Two Hundred Day Moving Average of $4.51 - Defense World
Daré Bioscience (NASDAQ:DARE) Stock Price Passes Below Two Hundred Day Moving Average of $4.59 - Defense World
Its Stock Has Paid Off Big Time For Dare Bioscience Inc - SETE News
Daré Bioscience Announces Publication in The Journal of - GlobeNewswire
Sildenafil cream shows promise for FSAD without common side effects - Investing.com
Daré Bioscience Announces Publication in The Journal of Sexual Medicine of Positive Safety Findings from the Phase 2b RESPOND Clinical Study of Sildenafil Cream, 3.6% - StockTitan
Daré Bioscience (NASDAQ:DARE) Shares Pass Below Two Hundred Day Moving Average of $4.62 - Defense World
Daré Bioscience, Inc. (NASDAQ:DARE) to Post FY2024 Earnings of ($0.33) Per Share, Brookline Capital Management Forecasts - Defense World
HC Wainwright Comments on Daré Bioscience, Inc.’s Q3 2024 Earnings (NASDAQ:DARE) - Defense World
Maxim Group Reiterates “Hold” Rating for Daré Bioscience (NASDAQ:DARE) - Defense World
Sildenafil Cream study suggests simplified patient reporting - Investing.com
0.93%
3.55%
자본화:
|
볼륨(24시간):